Compare Merck & Co., Inc. (MRK) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NEOS S&P 500 High Income ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while NEOS S&P 500 High Income ETF trades at $53.52. The key difference: Merck & Co., Inc. pays a 2.29% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals.
| MRK | SPYI | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $54.42 |
52-Week Low | $77.60 | $47.98 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SPYI trades at $53.65, down 0.39% on the day, with a neutral technical signal. Recent dividend distributions of $0.53-$0.54 highlight its income focus, though news articles caution about tax implications and return of capital. The ETF's covered-call strategy aims for high yield amid low S&P 500 dividend payouts.
Outlook remains mixed; high monthly income appeals, but structural risks and tax complexity warrant caution. Competition from JEPI and capital erosion concerns present headwinds, while demand for yield in retirement portfolios supports relevance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
